Call for Abstract

11th Annual Biomarkers and Clinical Research Congress, will be organized around the theme “Bio Markers: Future of Medical Diagnosis and Treatment”

Biomarkers 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Biomarkers 2019

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Clinical research biomarkers which are used for clinical purposes are known as clinical biomarkers. Clinical biomarkers provide active and influential way to understanding the scope of many diseases and epidemiology, random clinical trials, screening for drugs or disease diagnosis and prognosis. It is defined as changes in the constituents of cells or body fluids, these clinical biomarkers offer the means for standardized classification of a disease and risk factors that can extend the basic information about the underlying pathogenesis of diseases. The main researches in clinical biomarkers are done in the fields of drug discovery, pharmacogenomics, oncology, and disease diagnostics. Classes of Biomarkers in Clinical trials are segmented into Safety biomarkers & Efficacy biomarkers.


  • Track 1-1Prediction Biomarkers
  • Track 1-2Clinical research of biomarkers in drug discovery
  • Track 1-3Cell biology
  • Track 1-4Pathological biomarkers
  • Track 1-5New strategies for discovery
  • Track 1-6Biomarkers in Drug Discovery

Biomarkers and diagnostics play a crucial role in the outcomes and findings in clinical settings to enhance the quality of human health. Translational biomarkers and diagnostics can be applied in both preclinical and clinical setting. It should aim to translate the findings in fundamental research into medical practice and meaningful health outcomes. The characteristics for acceptable translational biomarkers and the various approaches to their selections including the latest trends and developments in translational biomarkers and diagnostics shall be discussed in this session. This session also discusses and reviews methods and requirements for qualification of translational biomarkers.


A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumour or a specific response of the body to presence of cancer. Genetic, epigenetic, proteomic, glycolic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. While some cancer biomarkers can be used to predict how aggressively your cancer will grow, and are therefore useful for assessing your prognosis, the most promising use of biomarkers today is to identify which therapies a patient’s cancer may or may not respond

  • Track 3-1Biomarker in Drug Design
  • Track 3-2Medicine Development in Oncology and Infectious Diseases
  • Track 3-3Drug discovery innovation and strategies
  • Track 3-4Phenotypic and genomic drug discovery
  • Track 3-5Computational chemistry and informatics for drug discovery

Biomarkers play an important role in prognosis and diagnosis of various cardiovascular and neurological diseases. The diseases which are deadly from ages has a possible treatment and easy diagnosis with the help of advancements in biomarkers through different diagnostics methods and imaging technologies. Cardiac biomarkers and neuro biomarkers has brought a great revolution in disease diagnosis and prognosis. These biomarkers are also used in many other non-cancerous diseases. Some of the important ones are Alzheimer’s disease, cardiovascular diseases, Huntington's disease, Neurodegenerative diseases, Diabetes and Behcet’s disease.


  • Track 4-1Biomarkers for Cardiovascular diseases
  • Track 4-2Biomarkers for Neurodegenerative diseases
  • Track 4-3Biomarkers for diabetes
  • Track 4-4Biomarkers for Behcet s disease
  • Track 4-5Biomarkers for Alzheimer
  • Track 4-6Biomarkers for Huntington s disease

Biomarkers focusing on two major areas of investigation: the early detection and prognosis. Early diagnosis and Prognostic Research encompasses the research addressing studies on the evaluation of medical tests, markers, prediction models and decision tools. Early diagnosis of cancer generally increases the chances for successful treatment by focusing on detecting symptomatic patients as early as possible. Delays in accessing cancer care are common with late-stage presentation, particularly in lower resource settings and vulnerable populations. The consequences of delayed or inaccessible cancer care are lower likelihood of survival, greater morbidity of treatment and higher costs of care, resulting in avoidable deaths and disability from cancer. Early diagnosis improves cancer outcomes by providing care at the earliest possible stage and is therefore an important public health strategy in all settings.


  • Track 5-1Challenges to biomarkers development in Immune system
  • Track 5-2Biomarkers discovery in Immunology
  • Track 5-3Biomarkers for Early Progressive Inflammatory & Immunological Diseases
  • Track 5-4Biomarkers of Disease Pathogenesis
  • Track 5-5Biomarkers under autoimmune system

Identification and validation of discovered gene or protein-based, network or dynamic network biomarkers with human diseases, patient phenotypes, or clinical applications, and accelerate the development of human disease-specific biomarkers for the early diagnosis, monitoring, evaluation, and prediction of diseases. Conditions including cancers, cardiovascular and metabolic diseases will be the focus of study. This section will promote the innovation and development of disease-specific biomarkers by integrating multidisciplinary aspects of science.


  • Track 6-1Cancer Biomarkers in clinical research
  • Track 6-2Diagnosis and treatment
  • Track 6-3Lung Cancer
  • Track 6-4Cervical Cancer
  • Track 6-5Ovarian Cancer
  • Track 6-6Breast Cancer
  • Track 6-7Prostate cancer
  • Track 6-8Testicular Cancer

The biomarker congress focuses on the biomarker validation which is an open-ended process with open-ended evidentiary standards, where every potential application of the biomarker needs to be supported by independent studies and datasets. One aspect that has created a revolution in the concept of biomarker research and development is the Next Generation Sequencing which is versatile analysis tool for medical and biological research. Next Generation Sequencing technology refers to one high-throughput DNA sequencing method. In a single experiment, it can determine the sequence of the target gene or full genome with a total size of larger than millions of base pairs. Sequencing thousands of genes or even genomes in one experiment is consequently made possible using this NGS technology.


  • Track 7-1Bioethics
  • Track 7-2Statistical protocols of biomarkers
  • Track 7-3Case studies

Genomics and Clinical development promise the development of biomarkers to a state to predict the risk of individual disease that allows early detection of the disease and improves diagnostic classification to better inform individualized treatment. Biomarkers are biological measurements that can be used to predict the risk of diseases, to allow early detection of diseases, to improve the selection of treatment and to monitor the outcome of therapeutic interventions. The main objective of the Human Genome Project was the identification and development of such biomarkers for "personalized, preventive and predictive medicine".This clinical conference focuses on biomarkers incorporating in the gene level into earlier stages of the clinical trials which help to separate the patients and help in the development of the biomarker and in case of clinical development this incorporation serves in multiple ways from guiding dose selection to selecting the mode of action to providing the strategy to know about to whom the a particular biomarker can be used.


  • Track 8-1Melanoma
  • Track 8-2Ovarian cancer
  • Track 8-3Endometrial cancer
  • Track 8-4Non-small cell lung cancer

Biomarker discovery requires high confidence identification of biomarker candidates with simultaneous quantitation information to indicate which proteins are changing to a statistically relevant degree in response to disease. Because of normal clinical or biological variability, candidate biomarkers identified in the discovery stage need to be validated across a large number of samples. The challenge is to develop a fast, targeted analysis method capable of analysing as many identified candidates as possible in minimally hundreds and potentially even thousands of samples.


  • Track 9-1Prognostic cancer biomarker
  • Track 9-2Pharmacodynamic cancer biomarker
  • Track 9-3Predictive cancer biomarker
  • Track 9-4Biomarkers for gastric cancer
  • Track 9-5Biomarkers for colorectal cancer
  • Track 9-6Uses of biomarkers in Cancer research

A key fixing in fruitful business is self-learning. Biomarkers-2019 plans to unite all current and growing bio-business people to share encounters and present new developments and difficulties inside the malignant growth network. Every year, over a million organizations work on the planet with about 5–10 of them being named high innovation organizations. Transforming thoughts into business adventures is precarious and the open door acknowledgment step is basic in new pursuit manifestations. This gestalt in the business visionary's view of the connection between the creation and last item is refined into a plan of action that depicts how the endeavour will profit or give a fitting come back to the potential financial specialists. Disease science is perplexing and quickly changing and requires specific information to comprehend the estimation of the advancement and its aggressive position in the business. This multi -day network wide gathering will be a very intelligent discussion which will get specialists zones extending from Biomarkers to flagging pathways to novel helpful ways to deal with the logical center point.


  • Track 10-1Drug development and usage
  • Track 10-2Drug development and usage
  • Track 10-3Metabolic Disorders
  • Track 10-4Genetic disorders
  • Track 10-5DNA biomarkers
  • Track 10-6Immune disorders